ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

23 1月 2025 07:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

22 1月 2025 15:01:00 条件 Nasdaq GlobeNewswire

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

22 1月 2025 07:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

21 1月 2025 16:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 1月 2025 07:00:01 条件 Nasdaq GlobeNewswire

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

18 12月 2024 07:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024

12 12月 2024 07:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer

10 12月 2024 08:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 11月 2024 07:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

14 11月 2024 07:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

07 11月 2024 15:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology Announces November Investor Conference Participation

04 11月 2024 07:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

01 11月 2024 16:30:00 条件 Nasdaq GlobeNewswire

ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference

09 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi

04 9月 2024 07:00:00 条件 Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

08 8月 2024 15:05:00 条件 Nasdaq GlobeNewswire

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

06 8月 2024 15:01:00 条件 Nasdaq GlobeNewswire

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

31 7月 2024 15:01:00 条件 Nasdaq GlobeNewswire

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

31 7月 2024 04:30:00 条件 Nasdaq GlobeNewswire

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

02 6月 2024 09:00:00 条件 Nasdaq GlobeNewswire